Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3839MR)

This product GTTS-WQ3839MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3839MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11606MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ11326MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ5198MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ2980MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ11170MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ874MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ13960MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ13786MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-1033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW